Clary, Douglas O. External Entity

Publications

Sort by

Selected publications

  • Phase I study of XL281 (BMS-908662), a potent oral RAF kinase inhibitor, in patients with advanced solid tumors.  Investigational new drugs2015 Academic Article GET IT

Other